Poseida therapeutics to present new clinical data from phase 1 study of allogeneic car-t p-bcma-allo1 in patients with relapsed/refractory multiple myeloma at 21st international myeloma society annual meeting

Latest data from poseida's lead investigational allogeneic car-t program, which is based on the company's unique stem cell memory t cell (tscm) platform company to host conference call on saturday, september 28, 2024, at 1 pm et / 10 am pt to review the p-bcma-allo1 phase 1 ims oral presentation data poseida initiates p-bcma-allo1 phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from roche san diego , sept. 5, 2024 /prnewswire/ -- poseida therapeutics, inc. (nasdaq: pstx), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that new clinical data from an ongoing phase 1 study of p-bcma-allo1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the 21st international myeloma society (ims) annual meeting, which is being held in rio de janeiro from september 25-28, 2024.
CAR Ratings Summary
CAR Quant Ranking